Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.08)
# 4,375
Out of 5,012 analysts
4
Total ratings
25%
Success rate
-39.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $23.90 | +280.75% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $2.85 | +321.05% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $86.72 | +29.15% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $23.90
Upside: +280.75%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $2.85
Upside: +321.05%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $86.72
Upside: +29.15%